Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs
dc.contributor.author | Janiczek, Nancy | en_US |
dc.contributor.author | Smith, David E. | en_US |
dc.contributor.author | Chang, Tsun | en_US |
dc.contributor.author | Ventura, Anthony | en_US |
dc.contributor.author | Mertz, Thomas E. | en_US |
dc.date.accessioned | 2006-04-19T13:36:46Z | |
dc.date.available | 2006-04-19T13:36:46Z | |
dc.date.issued | 1997-04 | en_US |
dc.identifier.citation | Janiczek, Nancy; Smith, David E.; Chang, Tsun; Ventura, Anthony; Mertz, Thomas E. (1997)."Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs." Journal of Pharmaceutical Sciences 86(4): 443-449. <http://hdl.handle.net/2027.42/34490> | en_US |
dc.identifier.issn | 0022-3549 | en_US |
dc.identifier.issn | 1520-6017 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34490 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9109046&dopt=citation | en_US |
dc.description.abstract | The pharmacokinetics and pharmacodynamics of pirmenol enantiomers were investigated in coronary artery ligated mongrel dogs. Reduction in frequency of premature ventricular complexes (PVCs) was determined following intravenous administration of 5-mg/kg doses of racemic pirmenol ( n = 5), (+)-pirmenol ( n = 4), and (−)-pirmenol ( n = 4), each given as a 5-min infusion. Electrocardiographic signals and blood samples were obtained serially over a 4-h period. Pirmenol enantiomer concentrations in plasma were determined by a stereospecific assay. Following the racemate dose, (−)-pirmenol had 47% lower clearance and 33% lower steady-state distribution volume than (+)-pirmenol. These differences could be mostly explained by stereoselective plasma protein binding, reflected in a 58% higher unbound fraction for (+)-pirmenol compared with (−)-pirmenol following racemate administration. Unbound pirmenol distribution volumes were nearly identical for both enantiomers, and unbound clearance was only 16% lower for (−)-pirmenol than (+)-pirmenol following administration of the racemate. Similar trends were observed for pirmenol enantiomers administered individually. Both pirmenol enantiomers were equally effective in arrhythmia suppression. The antiarrhythmic response of coronary artery ligated dogs to pirmenol was described by a sigmoid E max model, and no statistically significant differences were observed in the pharmacodynamic parameters [i.e., EC 50 (plasma concentration at 50% of maximum drug effect), S (constant that reflects the sigmoidal shape of the effect–concentration curve), and EC 90 (plasma concentration at 90% of maximum drug effect)] for (+)-pirmenol, (−)-pirmenol, or pirmenol racemate. | en_US |
dc.format.extent | 164943 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Chemistry | en_US |
dc.subject.other | Food Science, Agricultural, Medicinal and Pharmaceutical Chemistry | en_US |
dc.title | Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, 4302A Upjohn Center, 1310 E. Catherine Street, The University of Michigan, Ann Arbor, MI 48109-0504 ; Department of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105. | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, 4302A Upjohn Center, 1310 E. Catherine Street, The University of Michigan, Ann Arbor, MI 48109-0504 ; College of Pharmacy and Upjohn Center for Clinical Pharmacology, 4302A Upjohn Center, 1310 E. Catherine Street, The University of Michigan, Ann Arbor, MI 48109-0504. | en_US |
dc.contributor.affiliationother | Department of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105. | en_US |
dc.contributor.affiliationother | Department of Pharmacology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105. | en_US |
dc.contributor.affiliationother | Department of Pharmacology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105. | en_US |
dc.identifier.pmid | 9109046 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34490/1/7_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/(ISSN)1520-6017 | en_US |
dc.identifier.source | Journal of Pharmaceutical Sciences | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.